United Therapeutics Stock Revenue
| UTHR Stock | USD 378.13 1.13 0.30% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.3 B | 2.4 B |
United | Revenue |
United Therapeutics Company Revenue Analysis
United Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current United Therapeutics Revenue | 2.33 B |
Most of United Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of United
Projected quarterly revenue analysis of United Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of United Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in United Therapeutics' stock price.
United Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as Revenue. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.
| 0.4 | 0.48 | -0.65 | 0.31 | 0.65 | ||
| 0.4 | 0.8 | -0.65 | 0.99 | 0.66 | ||
| 0.48 | 0.8 | -0.5 | 0.76 | 0.51 | ||
| -0.65 | -0.65 | -0.5 | -0.63 | -1.0 | ||
| 0.31 | 0.99 | 0.76 | -0.63 | 0.63 | ||
| 0.65 | 0.66 | 0.51 | -1.0 | 0.63 |
Click cells to compare fundamentals
United Revenue Historical Pattern
Today, most investors in United Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various United Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of United Therapeutics revenue as a starting point in their analysis.
United Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
United Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, United Therapeutics reported 2.33 B of revenue. This is 69.48% lower than that of the Biotechnology sector and 213.3% higher than that of the Health Care industry. The revenue for all United States stocks is 75.33% higher than that of the company.
United Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.United Therapeutics is currently under evaluation in revenue category among its peers.
United Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
United Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in United Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of United Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing United Therapeutics' value.| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 621 K | Fuller & Thaler Asset Management Inc | 2024-09-30 | 568.4 K | Pacer Advisors, Inc. | 2024-06-30 | 561.8 K | Alliancebernstein L.p. | 2024-06-30 | 539.6 K | Amundi | 2024-06-30 | 473 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 438.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 434.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 434.5 K | Genworth Financial Wealth Mgmt Inc | 2024-09-30 | 420 K | Blackrock Inc | 2024-06-30 | 5.5 M | Vanguard Group Inc | 2024-09-30 | 4.4 M |
United Fundamentals
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.40 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 13.95 B | ||||
| Shares Outstanding | 44.64 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 98.16 % | ||||
| Number Of Shares Shorted | 2.21 M | ||||
| Price To Earning | 23.49 X | ||||
| Price To Book | 2.77 X | ||||
| Price To Sales | 6.12 X | ||||
| Revenue | 2.33 B | ||||
| Gross Profit | 1.78 B | ||||
| EBITDA | 1.39 B | ||||
| Net Income | 984.8 M | ||||
| Cash And Equivalents | 2.26 B | ||||
| Cash Per Share | 49.55 X | ||||
| Total Debt | 700 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 8.10 X | ||||
| Book Value Per Share | 136.74 X | ||||
| Cash Flow From Operations | 978 M | ||||
| Short Ratio | 5.72 X | ||||
| Earnings Per Share | 22.76 X | ||||
| Price To Earnings To Growth | 1.63 X | ||||
| Target Price | 382.22 | ||||
| Number Of Employees | 1.17 K | ||||
| Beta | 0.56 | ||||
| Market Capitalization | 16.88 B | ||||
| Total Asset | 7.17 B | ||||
| Retained Earnings | 6.03 B | ||||
| Working Capital | 2.75 B | ||||
| Current Asset | 1.28 B | ||||
| Current Liabilities | 440.82 M | ||||
| Net Asset | 7.17 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with United Stock
Moving against United Stock
| 0.7 | HLN | Haleon plc | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.65 | ZTS | Zoetis Inc | PairCorr |
| 0.57 | LLY | Eli Lilly Sell-off Trend | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.